Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TelOscope: CBX-663 in Advanced Cancers
NCT07779798Phase 1Recruiting
- Sponsor
- Crossbow Therapeutics
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBX-663 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 2 more, sponsored by Crossbow Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 24 months, Dose Limiting Toxicities (DLTs), Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and 32 more. Started Aug 2026; status: recruiting.
02
Drugs
CBX-663
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)solid tumorglioblastoma (GBM)
Beyond the preview
Go deeper on NCT07779798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779798.